CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
CTMX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
CytomX Therapeutics, Inc.NASDAQ: CTMX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $251K fell 34.8% year over year, behind the -26.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 50.8% from the prior quarter. Over 3 fiscal years it compounded at -17.4% a year.
Context
- Depreciation & amortization amounted to 1.8% of revenue in FY2025, up 0.5 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -34.8% toward the trailing-twelve-month pace of -26.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.38M USD
- Year-over-year change
- -22.2%
- 4-year CAGR
- -15.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.38M | -22.2% |
| FY2024 | 2024-12-31 | 1.77M | -18.7% |
| FY2023 | 2023-12-31 | 2.18M | -11.0% |
| FY2022 | 2022-12-31 | 2.44M | -9.7% |
| FY2021 | 2021-12-31 | 2.71M | — |
Depreciation & Amortization vs competitors
How CTMX compares with its peers on the latest reported figures
- CTMX's LTM Mar 2026 depreciation & amortization of $1.24M is the 8th highest of the 10 companies compared; the peer median is $6.7M.
- Its year-over-year change of -26.3% is the 7th highest of 9, against a peer median of -9.8%.
- Depreciation & amortization amounts to 3.5% of revenue for CTMX, versus a peer median of 6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $14.4M | -22.3% | +20.4% | 2.1% | |
| LTM Jun 2026 | $10.17M | -10.7% | +6.1% | 9.7% | |
| LTM Sep 2026 | $8.21M | -35.8% | -2.5% | 3.1% | |
| LTM Mar 2026 | $7.09M | -5.1% | -15.4% | 4.5% | |
| LTM Mar 2026 | $6.7M | -8.9% | -4.0% | 6.7% | |
| LTM Mar 2026 | $4.42M | +82.7% | +85.3% | 31.9% | |
| LTM Sep 2026 | $3.73M | +10.4% | +5.3% | 3333.9% | |
| LTM Mar 2026 | $1.24M | -26.3% | -17.4% | 3.5% | |
| LTM Mar 2026 | $1.19M | -63.3% | -7.7% | 1.5% | |
| LTM Jun 2024 | $931.31K | — | -25.6% | 114.2% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CTMX) | $6.7M | -9.8% | -2.5% | 6.7% | |
Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 114.19M | 111.65M | 77.68M | 83.38M | 68.73M |
| Selling, General & Admin | 39.16M | 42.85M | 30.02M | 29.73M | 29.84M |
| Operating Expenses | 153.35M | 154.5M | 107.7M | 113.11M | 98.57M |
| Depreciation & Amortization | 2.71M | 2.44M | 2.18M | 1.77M | 1.38M |
| EBITDA | (113.16M) | (96.87M) | 5.5M | 33.86M | (15.75M) |
| EBITDA Margin | -303.3% | -182.2% | 5.4% | 24.5% | -20.7% |
| Operating Income | (116.04M) | (101.34M) | (6.48M) | 25M | (22.36M) |
| Operating Margin | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% |
| Interest Income | 255K | 1.68M | 9.84M | 7.14M | 5.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 172K | 2.02M | 9.81M | 7.1M | 5.23M |
| Income Before Tax | (115.87M) | (99.32M) | 3.32M | 32.09M | (17.13M) |
| Pre-Tax Margin | -310.5% | -186.8% | 3.3% | 23.2% | -22.5% |
| Income Tax Expense | 0 | 0 | 3.89M | 224K | 238K |
| Net Income | (115.87M) | (99.32M) | (569K) | 31.87M | (17.37M) |
| Net Margin | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
| EPS (Basic) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| EPS (Diluted) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| Weighted Avg Shares | 64.15M | 65.74M | 73.81M | 84.44M | 137.94M |
| Weighted Avg Shares (Diluted) | 64.15M | 65.74M | 73.81M | 84.75M | 137.94M |
CytomX Therapeutics, Inc.
NASDAQ:CTMX
Intrinsic Alpha fair value
Locked
Current Price
$1.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.